Today, #
FlagshipFounded#
@moderna_tx, along with
@Merck released positive results from its Phase 3 INTerpath-001 study for intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, plus KEYTRUDA®, in patients with completely resected stage IIB-IV melanoma.
Data will be presented at the 2026 European Society for Medical Oncology (
@myESMO) Congress. #
BiggerLeaps#